Intrahepatic Cholangiocarcinoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
Recruiting
  • Hepatocellular Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • Houston, Texas
    MD Anderson Cancer Center
2022-03-31
Mar 31, 2022
I
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Bad Saarow, Germany
    HELIOS KLinikum Bad Saarow
2022-03-29
Mar 29, 2022
N
Recruiting
  • Acinar Cell Carcinoma
  • +93 more
  • Biospecimen Collection
  • +2 more
  • Birmingham, Alabama
  • +992 more
2022-04-05
Apr 5, 2022
K
S
Active, not recruiting
  • Intrahepatic Cholangiocarcinoma
  • Spokane, Washington
  • +22 more
2022-04-01
Apr 1, 2022
F
Withdrawn
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Zhongshan hospital, Fudan University
2022-03-22
Mar 22, 2022
V
Not yet recruiting
  • Hepatocellular Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • (no location specified)
2022-03-22
Mar 22, 2022
I
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Dresden, Germany
  • +7 more
2022-03-31
Mar 31, 2022
I
Not yet recruiting
  • Biliary Tract Cancer (CCA)
  • +4 more
  • (no location specified)
2022-03-29
Mar 29, 2022
D
Active, not recruiting
  • Bile Duct Cancer
  • Intrahepatic Cholangiocarcinoma
  • Melphalan/HDS
  • Cisplatin and Gemcitabine
  • Durham, North Carolina
  • +2 more
2022-03-23
Mar 23, 2022
G
Recruiting
  • Primary Liver Cancer
  • +3 more
  • Observation
  • Shanghai, P.R.China., China
    Eastern Hepatobiliary Surgery Hospital, Second Military Medical
2022-03-14
Mar 14, 2022
E
Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +6 more
2022-03-21
Mar 21, 2022
Y
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • HAIC Combined with Tislelizumab and Apatinib
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
2022-03-21
Mar 21, 2022
C
Not yet recruiting
  • Distal Bile Duct Adenocarcinoma
  • +7 more
  • Duarte, California
    City of Hope Medical Center
2022-03-09
Mar 9, 2022
F
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
2022-03-15
Mar 15, 2022
U
Recruiting
  • Hepatocellular Carcinoma
  • +5 more
  • Computed Tomography
  • +2 more
  • Seattle, Washington
  • +1 more
2022-02-24
Feb 24, 2022
B
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Combined Hepatocellular and Cholangiocarcinoma
  • Phoenix, Arizona
  • +40 more
2022-03-07
Mar 7, 2022
T
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
2022-02-22
Feb 22, 2022
T
Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Transcatheter arterial chemoembolization
  • +3 more
  • (no location specified)
2022-02-17
Feb 17, 2022
M
Enrolling by invitation
  • Intrahepatic Cholangiocarcinoma
  • +3 more
    • Dallas, Texas
      Methodist Dallas Medical Center
    2022-02-03
    Feb 3, 2022
    M
    Recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
    • MIV-818 (fostroxacitabine bralpamide) + lenvatinib
    • Antwerp, Belgium
    • +5 more
    2022-01-28
    Jan 28, 2022
    T
    Not yet recruiting
    • Intrahepatic Cholangiocarcinoma
    • DEB-TACE combined with Surufatinib and Camrelizumab
    • (no location specified)
    2022-02-09
    Feb 9, 2022
    U
    Recruiting
    • Biliary Tract Cancer
    • +7 more
    • Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
    • Chicago, Illinois
    • +1 more
    2022-01-18
    Jan 18, 2022